13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001920938
Total reported value
$2.7B
$2.7B
55 檔
31.4%
At the close of Q2 2025, Braidwell LP disclosed equity holdings valued at approximately $2.7B, spread across 55 reported holdings.
In Q2 2025, Braidwell LP adopted a defensive or profit-taking posture, trimming 19 positions and completely liquidating 16 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including GH 1.25 02-15-31, CAI, NBIX) accounted for 31.4% of total reported equity market value during Q2 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GH 1.25 02-15-31Bond | Guardant Health Inc | Bond | 8.77% | -3.42% | EXIT | |
| 2 | CAI | Caris Life Sciences Inc | Stock-Other | 6.69% | +0.66% | — | |
| 3 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 4.99% | -0.77% | -2.64% | |
| 4 | NVCR 0 11-01-25Bond | Novocure LTD | Bond | 4.71% | — | — | |
| 5 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.86% | -0.07% | +33.03% | |
| 6 | ARGX | Argenx Se - Adr | Stock-Healthcare | 3.67% | -1.46% | +20.92% | |
| 7 | RGEN 1 12-15-28Bond | Repligen CORP | Bond | 3.44% | -2.68% | +3.06% | |
| 8 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 3.42% | +0.20% | +81.61% | |
| 9 | ALGN | Align Technology Inc | Stock-Healthcare | 3.22% | — | -6.37% | |
| 10 | LEGN | Legend Biotech Corp-adr | Stock-Other | 3.09% | — | -14.64% | |
| 11 | IRTC 1.5 09-01-29Bond | Irhythm Holdings Inc | Bond | 3.08% | — | -18.60% | |
| 12 | NUVL | Nuvalent Inc-a | Stock-Other | 3.07% | -2.39% | EXIT | |
| 13 | NEO 0.25 01-15-28Bond | Neogenomics Inc | Bond | 2.98% | -2.44% | — | |
| 14 | CGON | Cg Oncology Inc | Stock-Other | 2.92% | -2.22% | EXIT | |
| 15 | IRWD 1.5 06-15-26Bond | Ironwood Pharmaceuticals | Bond | 2.68% | — | — | |
| 16 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.34% | +0.53% | +111.93% | |
| 17 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 2.32% | -0.05% | +72.75% | |
| 18 | APGE | Apogee Therapeutics Inc | Stock-Other | 2.20% | -1.34% | EXIT | |
| 19 | GKOS | Glaukos CORP | Stock-Healthcare | 2.13% | +0.32% | -3.37% | |
| 20 | DHR | Danaher CORP | Stock-Healthcare | 2.09% | +0.18% | — | |
| 21 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 1.88% | +0.14% | +5.87% | |
| 22 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 1.67% | -0.16% | +1.82% | |
| 23 | IRTC | Irhythm Holdings Inc | Stock-Healthcare | 1.58% | +0.48% | -46.08% | |
| 24 | ADPT | Adaptive Biotechnologies | Stock-Other | 1.54% | — | -19.58% | |
| 25 | GH | Guardant Health Inc | Stock-Healthcare | 1.49% | -0.72% | -36.88% | |
| 26 | ATEC | Alphatec Holdings Inc | Stock-Other | 1.38% | +1.30% | -14.66% | |
| 27 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.32% | +1.32% | — | |
| 28 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 1.30% | — | +0.11% | |
| 29 | KPTI 6 05-13-29 *Bond | Karyopharm Therapeutics | Bond | 1.22% | — | — | |
| 30 | TMDX | Transmedics Group Inc | Stock-Healthcare | 1.17% | +0.41% | -70.17% | |
| 31 | PEN | Penumbra Inc | Stock-Healthcare | 1.14% | -1.15% | EXIT | |
| 32 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.07% | -0.26% | -9.61% | |
| 33 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 1.04% | -0.01% | -43.83% | |
| 34 | HROW | Harrow Inc | Stock-Other | 0.91% | -0.18% | EXIT | |
| 35 | KIDS | Orthopediatrics CORP | Stock-Other | 0.81% | +0.20% | — | |
| 36 | IMCR 2.5 02-01-30Bond | Immunocore Holdings | Bond | 0.80% | — | -48.24% | |
| 37 | MRVI | Maravai Lifesciences Hldgs-a | Stock-Other | 0.69% | +1.04% | — | |
| 38 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 0.66% | — | -32.15% | |
| 39 | SION | Sionna Therapeutics Inc | Stock-Other | 0.64% | — | — | |
| 40 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.63% | — | +24.83% | |
| 41 | DXCM 0.25 11-15-25Bond | Dexcom Inc | Bond | 0.62% | — | — | |
| 42 | RGEN | Repligen CORP | Stock-Healthcare | 0.61% | +0.70% | +77.03% | |
| 43 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.58% | +0.98% | NEW | |
| 44 | CSTL | Castle Biosciences Inc | Stock-Other | 0.57% | — | +125.25% | |
| 45 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 0.53% | — | — | |
| 46 | GMED | Globus Medical Inc - A | Stock-Healthcare | 0.50% | — | — | |
| 47 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 0.48% | — | -38.32% | |
| 48 | XNCR | Xencor Inc | Stock-Other | 0.45% | — | — | |
| 49 | CELC | Celcuity Inc | Stock-Other | 0.40% | -0.11% | EXIT | |
| 50 | ATEC 0.75 08-01-26Bond | Alphatec Holdings Inc | Bond | 0.20% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CAI | Caris Life Sciences Inc | +6.7% | NEW | New buy |
| 2 | KPTI 6 05-13-29 *Bond | Karyopharm Therapeutics | +1.2% | NEW | New buy |
| 3 | NUVL | Nuvalent Inc-a | +1% | +39.83% | Add |
| 4 | KRYS | Krystal Biotech Inc | +0.9% | +81.61% | Add |
| 5 | GH 1.25 02-15-31Bond | Guardant Health Inc | +0.8% | — | Unchanged |
| 6 | XENE | Xenon Pharmaceuticals Inc | +0.7% | +33.03% | Add |
| 7 | SION | Sionna Therapeutics Inc | +0.6% | NEW | New buy |
| 8 | INSP | Inspire Medical Systems Inc | +0.6% | +72.75% | Add |
| 9 | UNH | Unitedhealth Group Inc | +0.5% | NEW | New buy |
| 10 | GMED | Globus Medical Inc - A | +0.5% | NEW | New buy |
| 11 | EWTX | Edgewise Therapeutics Inc | +0.4% | +111.93% | Add |
| 12 | NBIX | Neurocrine Biosciences Inc | +0.4% | -2.64% | Trim |
| 13 | ARGX | Argenx Se - Adr | +0.3% | +20.92% | Add |
| 14 | CSTL | Castle Biosciences Inc | +0.3% | +125.25% | Add |
| 15 | ADPT | Adaptive Biotechnologies | +0.3% | -19.58% | Trim |
| 16 | ALGN | Align Technology Inc | +0.3% | -6.37% | Trim |
| 17 | RGEN | Repligen CORP | +0.2% | +77.03% | Add |
| 18 | APGE | Apogee Therapeutics Inc | +0.2% | -4.02% | Trim |
| 19 | ISRG | Intuitive Surgical Inc | +0.1% | +1.82% | Add |
| 20 | ✓ | Crescent Biopharma Inc. | +0.1% | NEW | New buy |
| 21 | PEN | Penumbra Inc | +0.1% | +17.71% | Add |
| 22 | CGON | Cg Oncology Inc | +0.1% | — | Unchanged |
| 23 | CELC | Celcuity Inc | +0.1% | — | Unchanged |
| 24 | VKTX | Viking Therapeutics Inc | +0.1% | +0.11% | Add |
| 25 | RGEN 1 12-15-28Bond | Repligen CORP | +0.1% | +3.06% | Add |
| 26 | MDGL | Madrigal Pharmaceuticals Inc | +0.1% | +24.83% | Add |
| 27 | MRVI | Maravai Lifesciences Hldgs-a | 0% | — | Unchanged |
| 28 | SRZN | Surrozen Inc | 0% | NEW | New buy |
| 29 | HROW | Harrow Inc | 0% | -8.84% | Trim |
| 30 | ORKA | Oruka Therapeutics Inc | 0% | -3.03% | Trim |
| 31 | ATEC 0.75 08-01-26Bond | Alphatec Holdings Inc | — | — | Unchanged |
| 32 | DXCM 0.25 11-15-25Bond | Dexcom Inc | 0% | — | Unchanged |
| 33 | ✓ | Zura Bio LTD | 0% | — | Unchanged |
| 34 | TRVI | Trevi Therapeutics Inc | 0% | EXIT | Sold out |
| 35 | GKOS | Glaukos CORP | 0% | -3.37% | Trim |
| 36 | SKYE | Skye Bioscience Inc | -0.1% | EXIT | Sold out |
| 37 | BBNX | Beta Bionics Inc | -0.1% | EXIT | Sold out |
| 38 | IRTC 1.5 09-01-29Bond | Irhythm Holdings Inc | -0.1% | -18.60% | Trim |
| 39 | NVCR 0 11-01-25Bond | Novocure LTD | -0.1% | — | Unchanged |
| 40 | LUNG | Pulmonx CORP | -0.1% | — | Unchanged |
| 41 | NEO 0.25 01-15-28Bond | Neogenomics Inc | -0.1% | — | Unchanged |
| 42 | AARD | Aardvark Therapeutics Inc | -0.1% | EXIT | Sold out |
| 43 | ✓ | -0.1% | EXIT | Sold out | |
| 44 | SYRE | Spyre Therapeutics Inc | -0.1% | — | Unchanged |
| 45 | ATEC | Alphatec Holdings Inc | -0.1% | -14.66% | Trim |
| 46 | DHR | Danaher CORP | -0.1% | — | Unchanged |
| 47 | KIDS | Orthopediatrics CORP | -0.2% | — | Unchanged |
| 48 | ✓ | -0.2% | EXIT | Sold out | |
| 49 | XNCR | Xencor Inc | -0.2% | — | Unchanged |
| 50 | IRWD 1.5 06-15-26Bond | Ironwood Pharmaceuticals | -0.2% | — | Unchanged |
According to official SEC Form 13F filings, Braidwell LP reported a total U.S. public equity portfolio value of $2.7B across 55 disclosed positions in Q2 2025.
During Q2 2025, Braidwell LP's top holdings by market value included GH 1.25 02-15-31 (8.8%)、CAI (6.7%)、NBIX (5.0%). The largest single position, GH 1.25 02-15-31, represented 8.8% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
CAI
市值: $195.5M
Top Position Liquidated / Trimmed
BBIO 2.5 03-15-27
前期市值: $72.0M
In Q2 2025, Braidwell LP made 56 total portfolio adjustments, initiating 7 new buys, adding to 14 positions, trimming 19 holdings, and fully liquidating 16 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.